U.S. Patent 6,884,439: Scope, Claims, Expiration and Arsenic Trioxide Patent Landscape

U.S. Patent 6,884,439 protected a specific dosing and administration schedule for arsenic trioxide in human patients with acute promyelocytic leukemia, or APL. It did not claim arsenic trioxide as a chemical compound, an injectable formulation, a manufacturing process, or every use in leukemia. The patent’s protection was limited to method-of-treatment claims requiring approximately 0.15 mg/kg administered once daily and, in the dependent claims, specified induction, consolidation and repeat-cycle schedules.

The patent was listed for Trisenox, the arsenic trioxide product marketed in the United States. Its Orange Book patent term expired in 2021. The claims therefore no longer create an enforceable patent barrier to generic arsenic trioxide products or to use of the claimed regimen, subject to other unexpired patents and regulatory requirements.[1][2]

What patent is U.S. Patent 6,884,439?

U.S. Patent 6,884,439 is titled “Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide.” The patent issued in 2005 and covers therapeutic administration of arsenic trioxide to human APL patients.[1]

Field	Information
Patent	U.S. Patent 6,884,439
Title	Treatment of acute promyelocytic leukemia with arsenic trioxide
Patent type	Method-of-treatment patent
Therapeutic area	Acute promyelocytic leukemia
Active agent	Arsenic trioxide
Core dose	About 0.15 mg/kg once daily
Principal regimen	Induction to remission, followed by 25-dose consolidation
Listed product	Trisenox
Regulatory sponsor history	Cell Therapeutics, Cephalon and later Teva-related commercial ownership
Orange Book status	Listed patent associated with Trisenox
Listed expiration	September 24, 2021
Current enforceability	Expired

The patent is commercially important because its claims correspond closely to the clinical regimen used for intravenous arsenic trioxide in APL. The patent did not establish ownership of arsenic trioxide itself. Arsenic compounds were known before the patent, and arsenic trioxide had been investigated and used clinically for APL before the claimed regimen was patented.

What does claim 1 of U.S. Patent 6,884,439 cover?

Claim 1 requires all of the following elements:

A method for treating acute promyelocytic leukemia.
Treatment of a human patient.
Administration of arsenic trioxide.
A therapeutically effective amount.
A dose of about 0.15 mg/kg.
Administration once per day.

The claim is therefore narrower than a claim covering any arsenic trioxide treatment. It does not expressly require remission, a defined treatment duration, a particular formulation, intravenous administration, a specific infusion concentration, or a relapse setting.

The phrase “about 0.15 mg/kg” introduces a dosage range around the stated amount. The patent does not convert that phrase into an unlimited dose range. In an infringement dispute, the relevant range would depend on claim construction, specification support, prosecution history and the facts surrounding the administered dose.

The phrase “therapeutically effective dosage amount” is a functional limitation. The treatment must be intended and capable of producing a therapeutic effect in the claimed disease. A product label, treatment protocol, physician instructions and clinical records would be relevant evidence.

How do claims 2 through 11 define the induction and consolidation regimen?

Claims 2 through 11 create a series of narrower regimen claims built on claim 1.

Claims	Additional limitation
2	Continue arsenic trioxide until bone marrow remission; this is the first administration
3	Add a second administration of 0.15 mg/kg once daily for 25 doses
4	Begin the second administration 3 to 6 weeks after the first
5	Conduct the second administration for up to five weeks
6	Administer the second course at five doses per week
7	Repeat the second administration
8	Repeat it every 3 to 6 weeks
9	Complete between two and ten cycles of the second administration
10	Complete two cycles
11	Complete ten cycles

The practical regimen covered by the claims is:

induction with approximately 0.15 mg/kg arsenic trioxide once daily until bone marrow remission;
a consolidation course of 25 doses;
a 3-to-6-week interval between induction and consolidation;
consolidation over up to five weeks, generally five doses per week; and
repeat consolidation cycles at 3-to-6-week intervals, with claims directed to two through ten total cycles.

Claim 6 is particularly significant because 25 doses administered at five doses per week correspond to a five-week consolidation course. Claims 3 and 6 overlap substantially in the core number of doses but use different claim language. Claim 3 specifies 25 doses. Claim 6 specifies five doses per week and depends through claim 5, which limits the period to up to five weeks.

What do claims 12 through 21 cover?

Claims 12 through 21 provide an alternative induction framework. Instead of requiring treatment until bone marrow remission, claim 12 permits administration for up to 60 days.

The second claim branch then repeats the same consolidation structure:

25 doses of approximately 0.15 mg/kg once daily;
commencement 3 to 6 weeks after induction;
administration over up to five weeks;
five doses per week;
repeated consolidation every 3 to 6 weeks; and
two through ten total cycles.

The two claim branches can be summarized as follows:

Claim branch	Induction endpoint	Consolidation
Claims 1-11	Until bone marrow remission	25-dose course, repeatable every 3-6 weeks
Claims 12-21	Up to 60 days	25-dose course, repeatable every 3-6 weeks

Claims 2 through 11 and claims 12 through 21 are not identical. A protocol that ends induction at 60 days may fall within the second branch without satisfying the “until bone marrow remission” limitation in claim 2. Conversely, a protocol that reaches remission before 60 days may implicate both branches if the remaining limitations are met.

What does U.S. Patent 6,884,439 not claim?

The patent does not claim:

arsenic trioxide as a chemical compound;
all medical uses of arsenic trioxide;
treatment of acute myeloid leukemia generally;
treatment of cancers other than APL;
a specific intravenous formulation;
a defined arsenic trioxide concentration;
a container, vial or delivery device;
a manufacturing or purification process;
a pharmaceutical composition containing arsenic trioxide;
a combination with all-trans retinoic acid, or ATRA;
a particular patient genotype or PML-RARA status;
a particular relapse or newly diagnosed patient population;
oral arsenic trioxide products as such; or
a method that uses a materially different dose or schedule.

A formulation or manufacturing patent could have created separate rights even if a clinical method claim had expired. Conversely, expiration of this patent removed the specific method-of-treatment rights represented by claims 1 through 21.

When did U.S. Patent 6,884,439 lose exclusivity?

The Orange Book listed September 24, 2021 as the patent expiration date associated with U.S. Patent 6,884,439.[2] The patent is therefore expired, and the claims cannot presently be used as the basis for a new patent infringement action concerning conduct occurring after expiration.

The relevant exclusivity timeline is:

Date or period	Event
Before 2000	Arsenic trioxide clinical activity in APL was reported, particularly in China
September 2000	FDA approved Trisenox for relapsed or refractory APL
2005	U.S. Patent 6,884,439 issued
2011	Teva acquired Cephalon and its commercial portfolio
2018	FDA expanded Trisenox labeling to include newly diagnosed low- or intermediate-risk APL in combination with ATRA
September 24, 2021	Orange Book patent expiration
After expiration	Generic competition became possible without this patent as a blocking right

Patent expiration and FDA market exclusivity are separate concepts. A drug can lose patent protection while regulatory exclusivity, labeling restrictions, product-specific requirements or other patents remain relevant.

What is the Orange Book status of U.S. Patent 6,884,439?

The patent was listed in the FDA Orange Book for Trisenox, whose active ingredient is arsenic trioxide.[2] The listing connected the patent to an approved use of the product rather than to ownership of the active ingredient.

An Orange Book listing can affect an ANDA applicant because the applicant must address listed patents through certification or a statement that the relevant patent does not block approval. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.[3]

Because the patent expired in 2021, it no longer presents a current Orange Book patent obstacle. Historical Paragraph IV activity could still have affected launch timing before expiration, but a Paragraph IV certification against an expired patent does not create the same commercial delay as a challenge to a live listed patent.

Which companies challenged or competed against Trisenox?

Generic competition has involved companies seeking approval for arsenic trioxide injection or other arsenic trioxide products. The relevant commercial participants have included Teva as the Trisenox owner following its acquisition of Cephalon and generic manufacturers pursuing ANDA approval.

The competitive structure is different from a conventional small-molecule patent dispute involving a novel active ingredient:

arsenic trioxide is an old active ingredient;
the main branded protection was regimen-based;
the approved product required injectable pharmaceutical manufacturing and controls;
generic applicants could target the active ingredient without challenging ownership of the molecule; and
the expired regimen patent removed the principal method-of-use barrier.

A generic applicant could still face regulatory issues involving bioequivalence, injectable product quality, sterility, labeling carve-outs and pharmacovigilance. Those issues are commercial and regulatory barriers, not rights created by the expired patent.

What Paragraph IV risks applied to this patent?

Before expiration, an ANDA applicant using a Paragraph IV certification could have faced litigation under the Hatch-Waxman framework. The patent holder could assert that the proposed generic label or expected use would practice the claimed APL regimen.

The principal infringement theories would have focused on:

whether the proposed label instructed use at approximately 0.15 mg/kg once daily;
whether the labeled induction period matched remission-based or 60-day administration;
whether the label instructed 25-dose consolidation;
whether consolidation began 3 to 6 weeks after induction;
whether the label instructed five doses per week; and
whether the label instructed repeat cycles.

The strongest risk would have existed where the generic label reproduced the Trisenox regimen substantially as claimed. A label that omitted or carved out the patented use could reduce induced-infringement exposure, although physician prescribing and manufacturer communications would remain relevant.

The patent’s expiration eliminates forward-looking Paragraph IV launch risk for this patent. It does not eliminate risk under other patents, trade-secret claims, regulatory provisions or patent claims covering a different product or process.

How strong was the patent estate for Trisenox?

U.S. Patent 6,884,439 was commercially meaningful but structurally narrow.

Strength factor	Assessment
Active ingredient protection	None; arsenic trioxide was not newly claimed
Regimen specificity	High
Coverage of labeled dosing	Strong, because the claims track the clinical schedule
Formulation coverage	Not provided by the claims supplied
Manufacturing coverage	Not provided
Combination therapy coverage	Not expressly provided
Geographic scope	United States only
Duration	Expired in 2021
Workaround potential before expiration	Moderate, depending on dose, duration, schedule and labeling
Current blocking value	None from this patent because it is expired

The claims had meaningful scope against a generic label that copied the branded APL regimen. Their weakness was dependence on numerous clinical facts. A materially different dose, administration frequency, induction endpoint or consolidation interval could avoid one or more dependent claims, although doctrine-of-equivalents arguments might have been considered in litigation.

What formulation and manufacturing barriers remain after patent expiration?

The supplied claims do not protect the formulation or manufacture of arsenic trioxide. Post-expiration competition may still require:

sterile injectable manufacturing;
control of arsenic concentration and impurities;
stability data;
container-closure compatibility;
particulate and endotoxin control;
validated aseptic processing;
appropriate labeling and warnings; and
compliance with FDA current good manufacturing practice requirements.

These requirements can delay generic entry even where no enforceable method patent remains. They do not restore exclusivity to U.S. Patent 6,884,439.

How does this patent compare with patents for newer APL treatments?

U.S. Patent 6,884,439 is a legacy regimen patent. Newer APL products and treatment technologies may rely on different patent categories:

Patent category	Typical protected subject matter
Method of use	Disease subtype, line of therapy, combination or dosing schedule
Formulation	Concentration, excipients, stability or delivery format
Manufacturing	Purification, sterile processing or impurity control
Combination therapy	Arsenic trioxide with ATRA or chemotherapy
Biomarker selection	PML-RARA status or risk-stratified treatment
Device or packaging	Infusion systems, containers or administration kits

Unlike biologic products, arsenic trioxide does not create a conventional biosimilar pathway. A biosimilar application is not the relevant route because arsenic trioxide is a chemically defined small molecule. Competition proceeds through generic-drug pathways, including ANDAs and, where appropriate, other FDA application routes.

What licensing deals affected the commercial rights?

The academic and clinical development history of arsenic trioxide involved rights associated with the University of Hong Kong and commercial development by Cell Therapeutics. Cephalon later commercialized Trisenox, and Teva acquired Cephalon in 2011.[4][5]

Those transactions affected commercial control, distribution and product economics. They did not expand the literal scope of U.S. Patent 6,884,439. A license can authorize practice of patent rights, but it cannot make the claims cover formulations, indications or dosing schedules that the patent does not claim.

What litigation and settlement issues matter now?

The principal historical litigation issue would have been whether an ANDA applicant’s proposed label and anticipated use practiced the regimen claims. Settlement terms, if any, could have included delayed entry, licenses, authorized-generic arrangements or non-monetary provisions. Such agreements would have commercial significance only during the patent term.

After September 24, 2021, litigation based solely on infringement of U.S. Patent 6,884,439 is no longer a meaningful generic-entry constraint. Any current dispute would need to rely on another enforceable right or on conduct occurring during the patent’s term.

Key Takeaways

U.S. Patent 6,884,439 is a method-of-treatment patent for arsenic trioxide in human APL patients.
The independent claim requires approximately 0.15 mg/kg once daily.
Dependent claims cover remission-based induction, an alternative 60-day induction, 25-dose consolidation and repeat cycles every 3 to 6 weeks.
The patent does not claim arsenic trioxide itself, a formulation, manufacturing process or every APL treatment.
The patent was listed for Trisenox in the FDA Orange Book.
Its listed expiration date was September 24, 2021.
The patent is expired and no longer creates a current U.S. patent barrier to generic use of the claimed regimen.
Arsenic trioxide is a small molecule, so biosimilar analysis is not applicable.
Remaining market barriers are more likely to involve sterile injectable manufacturing, FDA approval, labeling and other patents rather than this expired patent.

FAQs About U.S. Patent 6,884,439

Does U.S. Patent 6,884,439 cover oral arsenic trioxide?

No. The supplied claims require administration of arsenic trioxide but do not expressly define an oral dosage form. Product-specific claims, regulatory labeling and infringement facts would determine whether an oral product falls within the claims. The patent itself is expired.

Does the patent cover arsenic trioxide used with all-trans retinoic acid?

The claims supplied do not require or expressly claim combination treatment with ATRA. A combination regimen could still satisfy the claims if every arsenic trioxide dose and timing limitation is met, but the patent does not grant a separate ATRA-combination right.

Could a generic manufacturer avoid the patent by using a different arsenic trioxide dose?

Before expiration, a materially different dose could avoid claim 1 and its dependent claims, depending on how “about 0.15 mg/kg” was construed. The patent’s expiration makes that historical design-around question commercially less important today.

Was U.S. Patent 6,884,439 a composition-of-matter patent?

No. It was a therapeutic method patent. It did not claim arsenic trioxide as a new chemical entity or claim a proprietary pharmaceutical composition.

What FDA exclusivity applied to Trisenox?

Trisenox received FDA approval for relapsed or refractory APL in 2000 and later received expanded labeling for newly diagnosed low- or intermediate-risk APL with ATRA. FDA regulatory exclusivity and the patent term were separate rights. Neither changes the expiration of U.S. Patent 6,884,439.[2][3]

References

United States Patent and Trademark Office. (2005). U.S. Patent No. 6,884,439, Treatment of acute promyelocytic leukemia with arsenic trioxide.
U.S. Food and Drug Administration. (2021). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Trisenox (arsenic trioxide) prescribing information.
Cephalon, Inc. (2010). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Teva Pharmaceutical Industries Ltd. (2011). Teva completes acquisition of Cephalon.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1397399	⤷ Start Trial
Australia	2002300339	⤷ Start Trial
Australia	747474	⤷ Start Trial
Brazil	9814857	⤷ Start Trial
Canada	2309652	⤷ Start Trial
China	1285743	⤷ Start Trial
Cyprus	1113856	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,884,439

Summary for Patent: 6,884,439